Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Krystal Biotech, Inc. Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.	United States of America	KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.	South Korea	307750
Kura Oncology, Inc. Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.	United States of America	KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Developing drugs & health goods by integrating oriental and Western medicine.	South Korea	009290
Kyivmedpreparat A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.	Ukraine	KMED
KYONGBO PHARMACEUTICAL CO., LTD. Manufactures APIs and finished drugs, offering global CDMO services from development to production.	South Korea	214390
KYORIN Pharmaceutical Co., Ltd. Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.	Japan	4569
Kyowa Kirin Co.,Ltd. Develops antibody medicines for oncology, nephrology, immunology, and allergy.	Japan	4151
KyungdongPharm Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.	South Korea	011040
KYUNG NAM PHARM.CO.,LTD. South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.	South Korea	053950